Novaferon Recombinant Cytokine Gene Derived Protein Injection

1. Indications and Usage
Chronic Hepatitis B: Treatment of HBeAg-positive chronic hepatitis B in adult patients.
2. Dosage and Administration
Route of Administration: For Intramuscular (IM) Injection ONLY.
Recommended Dosage:
Initial Phase: 10 μg administered once daily.
Maintenance Phase: After 12 weeks of daily administration, switch to 20 μg administered three times a week (every other day).
Critical Administration Instructions:
Duration: The total course of treatment should generally cover at least 36 weeks (12 weeks daily + 24 weeks three times a week).
Preparation: The solution is ready for use. Visually inspect before administration; do not use if turbidity or precipitates are observed.
3. Mechanism of Action
Interferon-like Activity: The drug binds to specific cell surface receptors, activating intracellular signaling pathways (e.g., JAK-STAT pathway) similar to natural interferons.
Antiviral Effects: It induces the expression of antiviral proteins (e.g., 2′,5′-OAS), inhibiting Hepatitis B virus (HBV) replication.
Immunomodulation: It enhances the activity of natural killer (NK) cells and T cells, promoting HBeAg seroconversion and HBsAg clearance.
4. Safety and Warnings
Contraindications: Hypersensitivity to the drug or its components; severe cardiac, hepatic, renal, or bone marrow dysfunction; epilepsy or CNS damage; and other severe conditions intolerant to the drug.
Embryo-Fetal Toxicity: Contraindicated in pregnancy due to potential abortifacient effects similar to interferons.
Autoimmune & CNS Effects: Use with caution in patients with a history of autoimmune disorders or severe CNS dysfunction.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Flu-like symptoms (fever in 88.3%, headache, muscle aches, fatigue), gastrointestinal reactions (nausea, anorexia, vomiting), mild myelosuppression (neutrophil and platelet reduction), and elevated liver enzymes (ALT).
Other Adverse Reactions: Injection site reactions, thyroid function abnormalities (e.g., elevated T3, decreased TSH), insomnia, and mild elevations in AST and bilirubin.
Clinical Research Highlights: Phase 3 trials demonstrated that the recombinant cytokine gene-derived protein significantly increased the HBeAg seroconversion rate compared to conventional interferon alfa-2b, with a similar safety profile.
6. Drug Interactions
Myelosuppressive Agents: Concomitant use with chemotherapy or other myelosuppressive drugs may exacerbate bone marrow suppression.
CNS Depressants: May potentiate the effects of sedatives or other CNS depressants.
Vaccines: The immunomodulatory effects may alter the immune response to vaccines.
7. Pharmaceutical Information
Chemical Composition: Active Ingredient: Recombinant Cytokine Gene Derived Protein (produced in E. coli).
Appearance: Clear, colorless liquid.
Packaging: 10 μg/1.0 mL or 20 μg/1.0 mL per single-dose vial.
Storage: Store at 2°C to 8°C, protected from light. Do not freeze.